Myriad Genetics (Nasdaq:MYGN) - Stock Price, News & Analysis

MYGN Stock Overview

A genetic testing and precision medicine company, develops genetic tests in the United States and internationally.

MYGN fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 19.3% below our estimate of its fair value

Revenue is forecast to grow 9.3% per year

Trading at good value compared to peers and industry

Risk Analysis

Significant insider selling over the past 3 months

Shareholders have been diluted in the past year

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Myriad Genetics, Inc. Competitors

Vericel

NasdaqGM:VCEL

US$2.0b

Kymera Therapeutics

NasdaqGM:KYMR

US$2.9b

Intellia Therapeutics

NasdaqGM:NTLA

US$2.1b

Novavax

NasdaqGS:NVAX

US$1.7b

Price History & Performance

Summary of all time highs, changes and price drops for Myriad Genetics
Historical stock prices
Current Share Price	US$23.39
52 Week High	US$29.30
52 Week Low	US$13.82
Beta	1.92
11 Month Change	-17.84%
3 Month Change	-9.93%
1 Year Change	55.21%
33 Year Change	-27.94%
5 Year Change	-27.94%
Change since IPO	335.16%

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Sep 20

Recent updates

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13

Myriad: Trying To Find Its Footing In An Evolving Industry

Sep 26

Shareholder Returns

	MYGN	US Biotechs	US Market
7D	-2.9%	0.6%	0.8%
1Y	55.2%	27.4%	38.3%

Return vs Industry: MYGN exceeded the US Biotechs industry which returned 26.9% over the past year.

Return vs Market: MYGN exceeded the US Market which returned 36% over the past year.

Price Volatility

Is MYGN's price volatile compared to industry and market?
MYGN volatility
MYGN Average Weekly Movement	6.2%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: MYGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MYGN's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	2,700	Paul Diaz	www.myriad.com

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.

Myriad Genetics, Inc. Fundamentals Summary

How do Myriad Genetics's earnings and revenue compare to its market cap?
MYGN fundamental statistics
Market cap	US$2.12b
Earnings (TTM)	-US$155.20m
Revenue (TTM)	US$802.20m

2.6x

P/S Ratio

-13.7x

P/E Ratio

Is MYGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYGN income statement (TTM)
Revenue	US$802.20m
Cost of Revenue	US$248.10m
Gross Profit	US$554.10m
Other Expenses	US$709.30m
Earnings	-US$155.20m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.71
Gross Margin	69.07%
Net Profit Margin	-19.35%
Debt/Equity Ratio	5.2%

How did MYGN perform over the long term?

See historical performance and comparison

MYGN Stock Overview

Rewards

Risk Analysis

Myriad Genetics, Inc. Competitors

NasdaqGM:VCEL

US$2.0b

NasdaqGM:KYMR

US$2.9b

NasdaqGM:NTLA

US$2.1b

NasdaqGS:NVAX

US$1.7b

Price History & Performance

Recent News & Updates

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Recent updates

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Insider recently sold US$321k worth of stock

Consensus EPS estimates fall by 25%

Price target increased by 7.6% to US$27.82

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

New minor risk - Financial position

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor